Breast Cancer Clinical Trial

Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer

Summary

RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vaccines made from gene-modified tumor cells may help the body build an immune response to kill tumor cells. Giving trastuzumab together with cyclophosphamide and vaccine therapy may kill more tumor cells.

PURPOSE: This phase II trial is studying the side effects of giving trastuzumab together with cyclophosphamide and vaccine therapy in treating patients with high-risk or metastatic breast cancer.

View Full Description

Full Description

OBJECTIVES:

Primary

To evaluate the safety of allogeneic sargramostim (GM-CSF)-secreting breast cancer vaccine in combination with trastuzumab (Herceptin®) and cyclophosphamide in patients with high-risk or metastatic HER2/neu-overexpressing breast cancer.
To measure the HER2/neu-specific CD4+ T-cell response by delayed-type hypersensitivity.
To measure the magnitude of HER2/neu-specific CD8+ T-cell responses by ELISPOT.

Secondary

To assess the impact of trastuzumab on immune priming in vivo by IHC.
To measure the impact of cyclophosphamide pretreatment on CD4+CD25+ regulatory T cells by flow cytometry.
To determine the time to disease progression.

Tertiary

To develop the tandem tetramer/CD107a cytotoxicity assay for HER2/neu-specific CD8+ T cells.
To measure novel T-cell responses induced by trastuzumab and cyclophosphamide-modulated vaccination.

OUTLINE: Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes once weekly beginning on day -1 of the first course of vaccination and continuing until the completion of the last course of vaccination. Patients also receive cyclophosphamide IV over 30 minutes on day -1 and allogeneic sargramostim (GM-CSF)-secreting breast cancer vaccine intradermally on day 0. Treatment with cyclophosphamide and the vaccine repeats every 27-42 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive a fourth course of cyclophosphamide and vaccine approximately 6-8 months after the first course.

Patients undergo delayed-type hypersensitivity testing and blood sample collection at baseline and periodically during study for immunologic laboratory studies. Blood samples are analyzed for serum GM-CSF levels by pharmacokinetic studies and for immune monitoring by ELISPOT and flow cytometry. Skin punch biopsies are also performed periodically and analyzed by IHC.

After completion of study treatment, patients are followed periodically.

View Eligibility Criteria

Eligibility Criteria

DISEASE CHARACTERISTICS:

Histologically confirmed adenocarcinoma of the breast, meeting one of the following criteria:

Metastatic disease

High-risk disease, defined as early-stage disease with pathologic involvement of locoregional lymph nodes

Patients who are/will be receiving standard adjuvant trastuzumab [Herceptin®] for high-risk disease will participate in this study during the single-agent trastuzumab portion of their therapy
No clinical or radiographical evidence of active disease
Not eligible for therapy of known curative potential for metastatic breast cancer
HER2/neu-overexpressing disease, defined as HER2/neu positive by IHC 3+ staining or by FISH+ amplification
Stable CNS disease allowed provided it has been adequately treated and is not under active treatment
Hormone receptor status not specified

PATIENT CHARACTERISTICS:

Menopausal status not specified
ECOG performance status 0-1
ANC > 1,000/mm^3
Platelet count > 100,000/mm^3
Serum creatinine < 2.0 mg/dL
Serum bilirubin ≤ 2.0 mg/dL (unless elevation is due to known Gilbert's syndrome)
AST/ALT ≤ 2 times upper limit of normal (ULN)
Alkaline phosphatase ≤ 5 times ULN
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception
Cardiac ejection fraction normal by MUGA OR ≥ 45% by ECHO
No other malignancies within the past 5 years, except for carcinoma in situ of the cervix, superficial nonmelanoma skin cancer, or superficial bladder cancer

No prior or currently active autoimmune disease* requiring management with systemic immunosuppression, including any of the following:

Inflammatory bowel disease
Systemic vasculitis
Scleroderma
Psoriasis
Multiple sclerosis
Hemolytic anemia or immune-mediated thrombocytopenia
Rheumatoid arthritis
Systemic lupus erythematosus
Sjögren syndrome
Sarcoidosis
Other rheumatologic disease
No symptomatic intrinsic lung disease or extensive tumor involvement of the lungs resulting in dyspnea at rest
HIV-negative
No evidence of active acute or chronic infection
No uncontrolled medical problems
No active major medical or psychosocial problems that could be complicated by study participation
No corn allergy
No known severe hypersensitivity to trastuzumab (except for mild to moderate infusion reactions that are easily managed and do not recur) NOTE: *Asthma or chronic obstructive pulmonary disease that does not require daily systemic corticosteroids allowed

PRIOR CONCURRENT THERAPY:

Any number of prior chemotherapy regimens for metastatic breast cancer allowed
Prior or concurrent trastuzumab in the adjuvant or metastatic setting allowed

More than 28 days since prior and no concurrent systemic oral steroids

Topical, ocular, or nasal steroids allowed
More than 28 days since prior and no concurrent chemotherapy, radiotherapy, or biologic therapy (except trastuzumab)
More than 28 days since prior and no concurrent participation in another investigational clinical trial involving a new drug
Concurrent endocrine therapy or bisphosphonates allowed

Study is for people with:

Breast Cancer

Phase:

Phase 2

Estimated Enrollment:

20

Study ID:

NCT00847171

Recruitment Status:

Completed

Sponsor:

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore Maryland, 21231, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 2

Estimated Enrollment:

20

Study ID:

NCT00847171

Recruitment Status:

Completed

Sponsor:


Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider